Skip to content

Glycocalyx Biomarkers in ARDS for Clinical Prognosis and Pulmonary Fibrosis

Predictive Value of Glycocalyx Biomarkers in Mechanical Ventilation of Patients With ARDS for Clinical Prognosis and Long-term Pulmonary Fibrosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03854565
Enrollment
336
Registered
2019-02-26
Start date
2019-05-01
Completion date
2019-12-31
Last updated
2019-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, Human, Endothelial Dysfunction, Mechanical Ventilation Pressure High

Keywords

ARDS, Endothelial Dysfunction, mechanical ventilation, Glycocalyx, pulmonary fibrosis, mortality

Brief summary

ARDS is a severe disease in ICU, and could induce high mortality. Glycocalyx is an important matrix construction which covers endothelial cells, it could protect endothelial cells injury and the glycocalyx biomarkers could predict pulmonary injury. Decorin is a member of the small leucine-rich proteoglycan (SLRP) family, contains a single glycosaminoglycan (GAG) chain and a core protein with 12 leucine-rich repeats. In the previous study, decorin is associated with cardiac and liver fibrosis, however, the effects of decorin on ARDS pulmonary fibrosis have not been clarified.

Interventions

DIAGNOSTIC_TESTGlycocalyx measurement,respiratory mechanics measurement

ELASA measure glycocalyx, measure plateau pressure, driving pressure

Sponsors

Southeast University, China
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

1. Age \> 18yrs and \<80yrs 2. Meet ARDS Berlin definition 3. With mechanical ventilation

Exclusion criteria

1. have chronic pulmonary disease 2. have use heparin or low molecular heparin or chondroitin sulfuric acid

Design outcomes

Primary

MeasureTime frameDescription
28 days mortality from patients involved in the study28 days28 days mortality from patients involved in the study

Secondary

MeasureTime frameDescription
CT and syndecan-1 to evaluate pulmonary fibrosis1mon, 3mon and 6 monthpulmonary fibrosis evaluated by biomarker and CT
pulmonary function test to evaluate pulmonary function1mon, 3mon and 6 monthpulmonary function evaluated by pulmonary function test

Countries

China

Contacts

Primary ContactChun C Pan, Dr
panchun1982@gmail.com+862583262550

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026